We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.00 | 0.13% | 1,585.50 | 1,585.00 | 1,585.50 | 1,588.50 | 1,575.00 | 1,579.50 | 839,673 | 12:49:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.23 | 65.21B |
From Apr 2019 to Apr 2024
TIDMGSK
RNS Number : 2285X
GlaxoSmithKline PLC
17 February 2017
GlaxoSmithKline plc (the 'Company')
Conditional Share Awards
On 15 February 2017 the Company granted conditional awards to the below Executive Directors and Persons Discharging Managerial Responsibilities. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (DABP) which was approved by shareholders on 20 May 2009.
Participants are required to defer 25% of any bonus earned into Ordinary Shares or ADSs and may be eligible to choose to invest up to an additional 25% (i.e. up to a maximum of 50%) (Deferred Bonus Award).
The Company will match the Deferred Bonus Award up to one-for-one depending on the achievement of performance targets (Matching Award). Details of the performance measures will be confirmed later in the year following shareholder approval of the Remuneration Policy at the AGM on 4 May 2017.
The performance period for the awards is the three financial years from 1 January 2017 to 31 December 2019.
The awards of deferred and matching shares have been granted as conditional awards over ADSs for US pre-tax participants and as nil-cost options over Ordinary Shares for all other participants.
The vesting date for these conditional awards will be the later of the date, following the end of the three year performance period, on which the Remuneration Committee determines the extent to which the performance measures have been achieved, the third anniversary of the Award Date or such other later date as determined by the Remuneration Committee.
The amounts shown below are the maximum amounts payable (exclusive of dividend reinvestment during the performance period). The actual pay-out will be determined by performance over the period. Progress against targets will be reported in the Company's Annual Report yearly.
Transaction notification
Hot Features
Premium
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Sir Andrew Witty
==== ====================================== ==========================================================
b) Position/status Chief Executive Officer
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) As Sir Andrew is retiring from the
Company on 31 March 2017 he is not eligible
for a matching award.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 34,353
======================================================================= ==========================
d) Aggregated information n/a(single transaction)
====
Aggregated volume
Price
==================================================================== =================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Ms E Walmsley
==== ====================================== ==========================================================
b) Position/status CEO Designate
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) Matching Award conditional award of
Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 31,945
======================================================================= ==========================
GBP15.770 31,945
======================================================================= ==========================
d) Aggregated information
====
Aggregated volume 63,890
Price GBP15.770
====================================== ===============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Mr R G Connor
==== ====================================== ==========================================================
b) Position/status President, Global Manufacturing & Supply
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) Matching Award conditional award of
Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 16,633
======================================================================= ==========================
GBP15.770 16,633
======================================================================= ==========================
d) Aggregated information
====
Aggregated volume 33,266
Price GBP15.770
====================================== ===============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Mr L Debruyne
==== ====================================== ==========================================================
b) Position/status President, Global Vaccines
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) Matching Award conditional award of
Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 27,957
======================================================================= ==========================
GBP15.770 27,957
======================================================================= ==========================
d) Aggregated information
====
Aggregated volume 55,914
Price GBP15.770
====================================== ===============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Mr S Dingemans
==== ====================================== ==========================================================
b) Position/status Chief Financial Officer
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) Matching Award conditional award of
Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 29,022
======================================================================= ==========================
GBP15.770 29,022
======================================================================= ==========================
d) Aggregated information
====
Aggregated volume 58,044
Price GBP15.770
====================================== ===============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Mr N Hirons
==== ====================================== ==========================================================
b) Position/status SVP, Global Ethics & Compliance
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) Matching Award conditional award of
Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 10,513
======================================================================= ==========================
GBP15.770 10,513
======================================================================= ==========================
d) Aggregated information
====
Aggregated volume 21,026
Price GBP15.770
====================================== ===============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Mr S A Hussain
==== ====================================== ==========================================================
b) Position/status President, Global Pharmaceuticals
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) Matching Award conditional award of
Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 29,059
======================================================================= ==========================
GBP15.770 29,059
======================================================================= ==========================
d) Aggregated information
====
Aggregated volume 58,118
Price GBP15.770
====================================== ===============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ================================================================================================
a) Name Mr B McNamara
==== ====================================== ========================================================
b) Position/status CEO, Consumer Healthcare
==== ====================================== ========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ================================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ====================================== ========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of ADSs (under the GlaxoSmithKline 2009
Deferred Annual Bonus Plan).
2) Matching Award conditional award of
ADSs (under the GlaxoSmithKline 2009 Deferred
Annual Bonus Plan) subject to performance
measures.
==== ====================================== ========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== ========================== ==========================
$40.110 6,128
=========================================== ========================== ==========================
$40.110 6,128
========================== ==========================
d) Aggregated information n/a (single transaction)
====
Aggregated volume
Price 12,256
$40.110
=========================================== ========================================================
e) Date of the transaction 2017-02-15
==== ====================================== ========================================================
f) Place of the transaction n/a
==== ====================================== ========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Mr D S Redfern
==== ====================================== ==========================================================
b) Position/status Chief Strategy Officer
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) Matching Award conditional award of
Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 13,231
======================================================================= ==========================
GBP15.770 13,231
======================================================================= ==========================
d) Aggregated information
====
Aggregated volume 26,462
Price GBP15.770
====================================== ===============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ================================================================================================
a) Name Dr M M Slaoui
==== ====================================== ========================================================
b) Position/status Chairman, Global Vaccines
==== ====================================== ========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ================================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ====================================== ========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of ADSs (under the GlaxoSmithKline 2009
Deferred Annual Bonus Plan).
2) As Dr Slaoui is retiring from the Company
on 30 June 2017 he is not eligible for
a matching award.
==== ====================================== ========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== ========================== =========================
$40.110 10,760
========================== =========================
d) Aggregated information n/a (single transaction)
====
Aggregated volume
Price
======================================= ============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ========================================================
f) Place of the transaction n/a
==== ====================================== ========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Ms C Thomas
==== ====================================== ==========================================================
b) Position/status SVP, Human Resources
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) Matching Award conditional award of
Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 19,916
======================================================================= ==========================
GBP15.770 19,916
======================================================================= ==========================
d) Aggregated information
====
Aggregated volume 39,832
Price GBP15.770
====================================== ===============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Mr P C Thomson
==== ====================================== ==========================================================
b) Position/status SVP, Communications & Government Affairs
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) Matching Award conditional award of
Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 6,269
======================================================================= ==========================
GBP15.770 6,269
======================================================================= ==========================
d) Aggregated information
====
Aggregated volume 12,538
Price GBP15.770
====================================== ===============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ================================================================================================
a) Name Mr D E Troy
==== ====================================== ========================================================
b) Position/status SVP & General Counsel
==== ====================================== ========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ================================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ====================================== ========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of ADSs (under the GlaxoSmithKline 2009
Deferred Annual Bonus Plan).
2) Matching Award conditional award of
ADSs (under the GlaxoSmithKline 2009 Deferred
Annual Bonus Plan) subject to performance
measures
==== ====================================== ========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== ========================== ==========================
$40.110 13,005
=========================================== ========================== ==========================
$40.110 13,005
========================== ==========================
d) Aggregated information n/a (single transaction)
====
Aggregated volume
Price 26,010
$40.110
=========================================== ========================================================
e) Date of the transaction 2017-02-15
==== ====================================== ========================================================
f) Place of the transaction n/a
==== ====================================== ========================================================
1. Details of PDMR/person closely associated with them ('PCA')
==== ==================================================================================================
a) Name Dr P J T Vallance
==== ====================================== ==========================================================
b) Position/status President, R&D
==== ====================================== ==========================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ==========================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==================================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ==========================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ==========================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ==========================================================
b) Nature of the 1) Deferred Bonus Award conditional award
transaction of Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan).
2) Matching Award conditional award of
Ordinary Shares (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ==========================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== =========================== ==========================
GBP15.770 21,632
======================================================================= ==========================
GBP15.770 21,632
======================================================================= ==========================
d) Aggregated information
====
Aggregated volume 43,264
Price GBP15.770
====================================== ===============================================================
e) Date of the transaction 2017-02-15
==== ====================================== ==========================================================
f) Place of the transaction n/a
==== ====================================== ==========================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEDLFFDLFEBBL
(END) Dow Jones Newswires
February 17, 2017 10:55 ET (15:55 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
